Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 12/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | CXCR6 | O00574 | 6/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245170 | 1.00 | LTA4H (0.60) | LTA4HKCNH2CXCR6EPHX2MEN1 | |
| SCHEMBL12222622 | 0.89 | LTA4H (0.72) | LTA4HKCNH2CXCR6MEN1KMT2A | |
| SCHEMBL2532921 | 0.89 | LTA4H (0.72) | LTA4HKCNH2CXCR6MEN1KMT2A | |
| SCHEMBL1903438 | 0.89 | LTA4H (0.72) | LTA4HKCNH2CXCR6MEN1KMT2A | |
| SCHEMBL13051105 | 0.88 | LTA4H (0.58) | LTA4HKCNH2CXCR6EPHX2MEN1 | |
| SCHEMBL743923 | 0.88 | LTA4H (0.58) | LTA4HKCNH2CXCR6EPHX2MEN1 | |
| SCHEMBL745109 | 0.86 | LTA4H (0.56) | LTA4HKCNH2CXCR6 | |
| SCHEMBL13051159 | 0.86 | LTA4H (0.56) | LTA4HKCNH2CXCR6 | |
| SCHEMBL12244441 | 0.85 | LTA4H (0.65) | LTA4HKCNH2CXCR6MEN1KMT2A | |
| SCHEMBL1907900 | 0.84 | LTA4H (0.73) | LTA4HKCNH2CXCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344008-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-01 | — | — | US | claimed |
| US-20110257153-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-10-20 | — | — | US | claimed |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| US-8367719-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8344008-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20110263639-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | Janseen Pharmaceutical NV | 2011-10-27 | — | — | US | disclosed |
| US-20110257153-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-10-20 | — | — | US | disclosed |
| US-7935725-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-03 | — | — | US | disclosed |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 2410/4885CXCR6 922/4885 |
| US-20110263639-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 2410/4885CXCR6 922/4885 |
| US-20110257153-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 2410/4885CXCR6 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.